

Future Leaders in the Biotech Industry

Featuring Rising Private Plays and Momentum-Building Public Companies

Friday, April 20, 2012

New York City

Millennium Broadway

Hotel & Conference Center

As *Future Leaders in the Biotech Industry* celebrates its 19th year, this turf neutral conference once again provides the industry's best venue — in a single day — to identify solid investment and partnering prospects. Wall Street and pharma executives will have the opportunity to assess private and public companies that not only survived the downturn with healthy financial profiles, but are poised to deliver on milestones that could lead to the next tier of valuations.

The longest-running independent Wall Street conference serving the biotech community, *Future Leaders* connects leading portfolio managers, bankers and analysts with investor-validated, milestone-rich private and public companies in key therapeutic areas, offering new investment opportunities and the chance to find stories with tier-jumping potential. In its first 18 years, *Future Leaders* has showcased more than 450 of these stories.

This one-day, turf-neutral meeting ensures the best access to C-level biotech executives and decision makers in the investment community, allowing your company to present to an audience of industry leaders assembled by BioCentury and Thomson Reuters.

BioCentury™



THOMSON REUTERS

Future Leaders in the Biotech Industry

Presenting Companies

Presenting Companies are hand-picked by BioCentury based on rigorous selection criteria, including investor validation, upcoming milestones, unpartnered assets and innovative science, informed by the collective intelligence of Thomson Reuters and the *Future Leaders* Sponsors.

Each Presenting Company provides a thorough 25-minute overview to fund managers who have been identified by Thomson Reuters as active biotech investors. At the 2011 *Future Leaders* conference, this hand-selected audience controlled more than \$800 billion in equity assets, with more than \$20 billion dedicated to biotech.

In addition, the turf-neutral setting provides unique access to a cross-section of sellside analysts and investment bankers in a single location, as well as representatives from pharmaceutical and top-tier biotech companies.

Private conference rooms and special events allow Sponsors, Presenting Companies and audience members to network and conduct one-on-one business meetings throughout the day.

"*Future Leaders* is an excellent venue to meet with top-tier investors, sell-side analysts, investment bankers, and important company representatives. Its unique format offers a company like ours the type of meaningful interactions that can benefit our company's business goals."

Jan Turek
President & CEO, Biolex Therapeutics

Benefits for Presenting Companies


- Conference marketing focused on highly qualified financial professionals, including buy-side, sell-side and banking institutions
- Targeted marketing to key business development professionals in pharma and big biotech
- High-level sponsors validate conference value
- Full 25-minute presentation to investors followed by 30-minute breakout session
- Opportunity to webcast presentation to reach additional audiences
- Private meeting space available without additional charge
- Designated Presenting Company table at Networking Luncheon
- Full company profile from *BCIQ: BioCentury Online Intelligence™* available to all registrants
- Company logo posted on official 2012 *Future Leaders* website for one year after event

For the 2011 list of Presenting Companies that participated in *Future Leaders*, please go to the *Future Leaders* website at www.biocentury.com.

"*Future Leaders* had a great audience and the mix was exceptionally good: A lot of investors and a range of sellside analysts, clinical experts and pharmaceutical business development representatives. We had the most intense breakout session we've ever had."

Dr. Christian Itin,
President & CEO, Micromet

2011 Attendees Represented a Broad Cross-Section of The Industry



Future Leaders in the Biotech Industry

Sponsors

Future Leaders pioneered the “turf-neutral” concept on Wall Street, creating an open door for all members of the financial community to do business with independently selected Presenting Companies.

This approach has been possible because of the durable support of the Gold and Contributing Sponsors, whose endorsement enables BioCentury and Thomson Reuters to make this truly “A Collaborative Gathering of the Corporate and Investment Communities.”

Benefits for Sponsors

- Nominate Presenting Companies
- Exclusive access to the presenting company executives: last year’s meeting included more than 60 C-level executives, including 34 CEOs and/or presidents and 20 CFOs/CBOs.
- Sponsor recognition in targeted promotions to BioCentury’s and Thomson Reuters’ proprietary databases, including:
 - Announcements in *BioCentury: The Bernstein Report on BioBusiness*® and *BioCentury Extra*, BioCentury’s daily executive news service
 - Promotional e-mails to an international industry audience
- Advertising on “BioCentury This Week” TV website at www.biocenturytv.com
- Access to the pre-registration list in advance of the meeting
- Access to onsite meeting space
- Recognition of your firm on the Conference Book cover
- Your firm’s logo posted on the 2012 *Future Leaders* website for one year after event
- Recognition in welcoming remarks
- Opportunity to introduce Presenting Companies to the audience on day of conference
- Distribute your company’s collateral at venue

2011 Contributing Sponsors



“The quality of presenting companies is what makes *Future Leaders* such a success year after year. It attracts a broad spectrum of public investors, venture capitalists and service providers who want to hear where the ‘future leaders’ are taking this industry in the coming years.”

**Jonathan Silverstein, General Partner,
OrbiMed Advisors**

“Over the years we have enjoyed the visibility the *Future Leaders* conference brings to Domain’s portfolio companies. The turf-neutral nature of the meeting is a wonderful venue for our companies to meet many interested parties involved in key aspects of the industry.”

Nicole Vitullo, Partner, Domain Associates

About BioCentury

BioCentury Publications, Inc. provides essential industry intelligence across the full spectrum of the industry’s value chain from research through commercialization, reaching a global audience of biotech and pharmaceutical executives and investors. With 20 years of service, the company is privately owned and does not invest in or recommend individual stock purchases; therefore, subscribers benefit from BioCentury’s independent perspective and trustworthy content, built on deep knowledge and data-driven analysis. For more information, please visit www.biocentury.com.

BioCentury™

About Thomson Reuters

Thomson Reuters is the world’s leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, healthcare and science and media markets, powered by the world’s most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs 55,000 people and operates in over 100 countries. For more information, go to www.thomsonreuters.com.



THOMSON REUTERS